Healthcare / Drug Manufacturers - Specialty & GenericBSE
$1.73
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 14%
FCF escenarios
weak_data · normalized FCF $-6.5M · quality 39.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
3/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$33M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-83.1%
↓Gross Margin
N/A
•Debt/Equity
6.90
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.64x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-9.0M · FCF $-5.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | — | $323750.00 |
| Net Income | $-9.0M | $-9.0M | $-8.3M | $-10.5M | $-1.4M |
| EBITDA | $-7.2M | $-7.2M | $-7.1M | $-9.2M | $-4.1M |
| EPS | -0.47 | -0.47 | -0.43 | -0.55 | -0.07 |
| Gross Margin | — | — | — | — | -58.0% |
| Operating Margin | — | — | — | — | -3653.4% |
| Net Margin | — | — | — | — | -437.3% |
| Balance Sheet | |||||
| Debt/Equity | 6.90 | 6.90 | 3.69 | 2.42 | 1.52 |
| Current Ratio | 0.23 | 0.23 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-5.7M | $-5.7M | $-6.5M | $-9.8M | $-43.5M |
| Returns | |||||
| ROE | -83.1% | -83.1% | -42.2% | -37.6% | -3.7% |
| Valuation | |||||
| P/B | 3.06 | 3.06 | 3.12 | 1.44 | 0.69 |
| Growth & Yield | |||||
| EPS Growth | -9.3% | -9.3% | 21.8% | -685.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-37.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.43 → -0.47
Residual
-37.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.